Danish biotech Breye Therapeutics has raised €67.5 million to advance an oral eye disease drug candidate into a Phase 2 ...

Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on ...

Sweden’s Nanexa has granted Novo Nordisk a global license to use its PharmaShell drug delivery technology in up to five ...

Swiss biotech Addex Therapeutics has regained global rights to a GABA-B drug portfolio from Indivior, including a candidate ...

The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: ...

Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an ...

GSK has agreed to acquire full global rights to a preclinical trispecific T-cell engager for multiple myeloma from ...

Thomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most ...

Novartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the ...

Roche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped ...

PBIOVIAN has appointed Ponchi Kantt-Neaz as Global Executive Business Director, marking an important milestone in the company’s global commercial strategy and further strengthening its commercial ...

Roche signed two research partnerships on Sept. 24: one with Atavistik Bio to discover drugs for cardiovascular, renal and metabolic diseases, and another with Earendil Labs to develop cancer ...